Serum FGF21 is markedly decreased in response to exercise training, offering a novel mechanism to explain the observed reduction in liver fat, improvement in serum biomarkers of liver fibrosis, and gains in cardiorespiratory fitness in patients with NASH who do exercise. Here, FGF21 is linked to Hepatic fibrosis.